A new aligned pathway between NICE and the Medicines and Healthcare products Regulatory Agency is set to bring medicines to patients faster in England, with decisions on licensing and value expected to run alongside each other from 1 April. The move is part of wider efforts to improve access to treatment and give companies greater certainty in planning.
Joint process aims to cut delays
NICE said the change could make medicines available 3 to 6 months sooner, while also supporting a more efficient approval process across the health system. Alongside the pathway, the organisations are also launching an improved Integrated Scientific Advice service designed to support developers earlier in the process.
The announcement follows commitments in the government’s 10 Year Health Plan for England and Life Sciences Sector Plan, which call for closer working between NICE and the MHRA to help patients receive new treatments sooner.
What the new pathway means for patients
For patients, the main impact is expected to be faster access to medicines once they have been assessed for both safety and value. For companies, the combined route is intended to reduce uncertainty by bringing the two decisions into a more coordinated timeline.
NICE said the approach is designed to help medicines reach the health service more quickly without weakening the assessment process. The change is also expected to support broader efficiencies for medicines and medical devices across the UK health and care system.
The announcement comes at a time when faster access to effective treatment remains a major priority for the NHS, particularly as demand continues to rise and the system looks for ways to improve productivity. More information is available from NICE.
In practice, the new pathway marks a significant shift in how medicines may move from regulatory review to NHS adoption. If it performs as intended, it could streamline one of the most important steps between scientific development and real-world patient care.
Sursa foto: Imagine generată AI
